Table 4.

Pain-related diagnoses in patients with new pregabalin/gabapentin (P/G) prescriptions in 2015 (n=25 251)

Pain-related diagnoses			Number of insured persons	%
A	1	Non-neuropathic pain (exclusive)	2951	11.7
B	2	Typical neuropathic pain disorder (exclusive) (demonstrable benefit of a P/G therapy)	1218	4.8
C	3	Pain with possible neuropathic or partial-neuropathic cause (exclusive) (no demonstrable benefit of P/G)	3025	12.0
D	1+2		1295	5.1
E	1+3		10 756	42.6
F	2+3		1010	4.0
G	1+2+3		2990	11.8
H	neither 1, 2 nor 3		2006	7.9